Travel rules are tightening, vaccine hopes are being tested—and the fine print matters. Quick recap for anyone just joining us: Bundibugyo medical tools are still a major uncertainty in the DRC outbreak. There is no authorized vaccine or specific antiviral for this Ebola species. Before today, the question was whether tools built for Zaire ebolavirus could help. Earlier evidence suggested cross-reactive antibodies, while WHO had added a validated diagnostic test and started an international treatment trial. This is Ebola Watch. The U.S. has a hard travel rule in place. WHO is weighing a vaccine trial, and a treatment study is already enrolling—so let's start with who can get on a plane home. This one's from CDC:
Travel from Democratic Republic of the Congo (DRC): Travelers, including U.S. citizens and U.S. nationals, who have been in DRC within 21 days before departure will not be allowed to board commercial flights with U.S. destinations. These travelers should plan to remain outside the United States for at least 21 days after they leave DRC.
If you were in the DRC anytime in the 21 days before departure, CDC says you can't board a commercial flight headed to the U.S. That includes Americans. Your itinerary stops there; this isn't just an airport questionnaire. And the clock starts when you leave the DRC. CDC says travelers should plan to remain outside the United States for at least 21 days afterward. Even an intermediate stop in DRC counts, whether or not you leave the plane. So a traveler stuck in Kinshasa can't simply connect through Europe and land in New York. They need a three-week buffer in the return plan—and outbreak-affected provinces may add local exit requirements. Keep the tiers straight: travel to Uganda or South Sudan, without DRC exposure, means routing through designated U.S. airports for enhanced screening. DRC exposure means no boarding on commercial U.S.-bound flights for 21 days. CDC has drawn a deliberate distinction there. Anadolu Agency, with Beyza Binnur Donmez:
The World Health Organization (WHO) experts on Friday recommended prioritizing the licensed Ebola vaccine Ervebo for evaluation in a randomized clinical trial amid the ongoing Bundibugyo virus disease outbreak in the Democratic Republic of the Congo. The WHO said in a statement that its Technical Advisory Group on candidate vaccine prioritization made the recommendation after reviewing new preliminary data showing that Ervebo offered "some level of cross-protection" against Bundibugyo virus disease in animal studies, particularly against death.
On the Bundibugyo front, WHO experts want Ervebo tested in a randomized trial, not routinely rolled out. That distinction is the whole story. Because Ervebo is licensed for Zaire ebolavirus, and this outbreak is Bundibugyo. The encouraging data come from animals, pointing to some protection against death—not proof that it prevents infection or stops transmission. Exactly. The advisory group found no safety concern with studying it among contacts of cases, but whether it works in people still has to be shown. It's a credible signal worth testing, but listeners shouldn't assume a vaccine answer is already in hand. So, cautiously promising—and very much still in the evidence-building phase. For families watching from abroad, don't let the word “licensed” erase the strain-specific fine print. Médecins Sans Frontières writes:
The PARTNERS trial is the WHO sponsored international clinical research trial conducted through close collaboration between national health authorities, research institutions, outbreak response partners, and international organizations. It aims to rapidly generate high-quality evidence on the safety and efficacy for patients who tested positive for Bundibugyo virus disease, of two promising treatments - MBP134 and Remdesivir.
The treatment story has an address: Elikya Ebola Treatment Centre in Bunia. Dr. Olivier Kasita says the WHO-sponsored PARTNERS trial is testing MBP134 and remdesivir in a randomized study for people who test positive for Bundibugyo. And that randomization matters. Participants are assigned across four groups: both medicines together, MBP134 alone, remdesivir alone, or the comparison arm. That's how clinicians can tell a hopeful signal from evidence strong enough to guide care. Which also means: don't hear “trial” and assume “treatment proven.” Patients in Bunia are helping answer whether either drug works against this strain—and that answer isn't available yet. There is meaningful coordination on the ground: WHO sponsorship, national health authorities, research partners, and an MSF-supported centre working in the same clinical structure. For families arriving at Elikya, care and research are being organized together. Gulf News is tracking this. Four thousand fifty-three confirmed cases, 1,850 deaths, and UNICEF says 330 of those deaths are children. Those numbers do not suggest this is under control. And “confirmed” matters here: 4,053 is the reported confirmed-case total, not a combined suspected-and-confirmed figure. It's a grim threshold, but it doesn't tell us the full scale of transmission on its own. We've laid out the CDC restriction, the vaccine evaluation, and the treatment trial in Bunia—tools are becoming visible. Meanwhile, essential child and maternal health services are being disrupted across the country. The response has to reach ordinary clinics, fast. Gulf News says there is no sign of slowing. With 330 children reported dead by UNICEF, every interruption in routine care adds to the outbreak's harm. If Ebola Watch is part of your routine, please subscribe and leave us a review wherever you're listening. Your reviews help other people find the show, and we're grateful to have you with us.
Links to every story are in the show notes if you'd like to read more. Thanks for listening, and we'll be back with the latest. That's Ebola Watch for today. This is a Lantern Podcast.